Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8693325 | 0.89 | POLB (0.37) | POLBTSHR | |
| SCHEMBL8693335 | 0.89 | POLB (0.37) | POLBTSHR | |
| Upenazime SCHEMBL1477985 | 0.89 | POLB (0.37) | POLBTSHR | |
| SCHEMBL15144439 | 0.87 | POLB (0.36) | POLBTSHR | |
| SCHEMBL15135657 | 0.87 | POLB (0.36) | POLBTSHR | |
| SCHEMBL8362134 | 0.82 | POLB (0.33) | POLBTSHR | |
| SCHEMBL8362130 | 0.82 | POLB (0.33) | POLBTSHR | |
| SCHEMBL7118056 | 0.82 | POLB (0.33) | POLB | |
| SCHEMBL7118054 | 0.82 | POLB (0.33) | POLB | |
| SCHEMBL8476513 | 0.80 | PAOX (0.38) | POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321287-A1 | RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321287-A1 | RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC | GRPR, GIPR, SCTR | POLB 4701/4885TSHR 93/4885GRIN2D 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.